NCT05449691

Brief Summary

In this feasibility study, 60 women undergoing reconstruction will be randomly allocated to receive biological or synthetic mesh and followed for 6 months. The findings will tell us if patients and surgeons are comfortable with not being able to choose which mesh is used for the operation. In the larger surgical study, the investigators plan to measure patients' satisfaction with the reconstruction, patients' quality of life, complications from the operation and costs over 5 years.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable breast-cancer

Timeline
Completed

Started Nov 2023

Geographic Reach
1 country

5 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 4, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 8, 2022

Completed
1.3 years until next milestone

Study Start

First participant enrolled

November 2, 2023

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2026

Completed
Last Updated

September 10, 2025

Status Verified

September 1, 2025

Enrollment Period

2.5 years

First QC Date

July 4, 2022

Last Update Submit

September 3, 2025

Conditions

Keywords

breast reconstructionmeshacellular dermal matrixsynthetic meshbreast cancerpatient reported outcome

Outcome Measures

Primary Outcomes (4)

  • Clinician acceptance

    Proportion of eligible women offered the trial

    2 years

  • Patient acceptance

    Proportion of women offered the trial who participate in the trial

    2 years

  • Recruitment rate

    Number of patient recruited per year per site

    2 years

  • Compliance with allocated intervention

    Number of patients not complying with randomisation allocation

    2 years

Study Arms (2)

Biological Matrix

ACTIVE COMPARATOR

Participants will undergo immediate breast reconstruction using biological matrix and implant

Procedure: One-stage immediate breast reconstruction

Synthetic Mesh

EXPERIMENTAL

Participants will undergo immediate breast reconstruction using synthetic mesh and implant

Procedure: One-stage immediate breast reconstruction

Interventions

One-stage mesh assisted implant breast reconstruction

Biological MatrixSynthetic Mesh

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Female age ≥ 18 Women undergoing mastectomy and immediate one-stage mesh assisted implant breast reconstruction as standard treatment

You may not qualify if:

  • Revision reconstruction surgery Delayed reconstruction surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

University Hospitals of Derby and Burton NHS Foundation Trust

Derby, DE22 3NE, United Kingdom

RECRUITING

Wycombe Hospital

High Wycombe, United Kingdom

RECRUITING

Castle Hill Hospital

Hull, United Kingdom

RECRUITING

University Hospitals of Leicester NHS Trust

Leicester, United Kingdom

RECRUITING

Nottingham City Hospital

Nottingham, United Kingdom

RECRUITING

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Amit Goyal, MS, MD, FRCS

    University Hospitals of Derby and Burton NHS Foundation Trust

    STUDY CHAIR

Central Study Contacts

Amit Goyal, MS, MD, FRCS

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
Single blind masking
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief Investigator

Study Record Dates

First Submitted

July 4, 2022

First Posted

July 8, 2022

Study Start

November 2, 2023

Primary Completion

April 30, 2026

Study Completion

April 30, 2026

Last Updated

September 10, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations